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Abstract
Background: Few studies have estimated prevalence of neurocysticercosis (NCC) among persons with epilepsy in sub-
Saharan Africa. While the limitations of serological testing in identification of NCC are well known, the characteristics of
persons who are misdiagnosed based on serology have not been explored. The first objective of this pilot study was to
estimate the prevalence of NCC in epilepsy outpatients from an area of South Africa endemic for cysticercosis. The second
objective was to estimate the accuracy of serological testing in detecting NCC in these outpatients and characterize sources
of disagreement between serology and neuroimaging.
Methodology/Principal Findings: All out-patients aged 5 or older attending the epilepsy clinic of St. Elizabeth’s Hospital in
Lusikisiki, Eastern Cape Province, between July 2004 and April 2005 were invited to participate. Epidemiological data were
collected by local study staff using a standardized questionnaire. Blood samples were tested by ELISA for antibody and
antigen for Taenia solium. Four randomly chosen, consenting participants were transported each week to Mthatha for brain
CT scan. The proportion of persons with epilepsy attending St. Elizabeth clinic with CT-confirmed NCC was 37% (95% CI:
27%–48%). Using CT as the gold standard, the sensitivity and specificity of antibody testing for identifying NCC were 54.5%
(36.4%–71.9%) and 69.2% (52.4%–83.0%), respectively. Sensitivity improved to 78.6% (49.2%–95.3%) for those with active
lesions. Sensitivity and specificity of antigen testing were considerably poorer. Compared to false negatives, true positives
more often had active lesions. False positives were more likely to keep pigs and to have seizure onset within the past year
than were true negatives.
Conclusions/Significance: The prevalence of NCC in South African outpatients with epilepsy is similar to that observed in
other countries where cysticercosis is prevalent. Errors in classification of NCC using serology alone may reflect the natural
history of NCC.
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Introduction
Neurocysticercosis (NCC) results when the central nervous
system (CNS) is invaded by the larval stage of Taenia solium,a
zoonotic cestode transmitted between humans and pigs. Humans
infected with the adult tapeworm, a disease called taeniasis,
contaminate the environment with the parasites’ eggs contained in
the proglotids that are shed in their feces. Pigs become infected
with the eggs and the larvae migrate to several tissues, including
muscles. Humans acquire taeniasis when eating insufficiently
cooked, infected pork meat. In areas where sanitation and
personal hygiene are poor, humans can also become infected
with the eggs present in feces of people infected with taeniasis.
Eggs develop to larvae, enter the CNS and can lodge in the
parenchyma, subarachnoid space, or the ventricular system of the
brain and are sometimes seen in the eye [1]. Since each proglotid
contains about 40,000 eggs and infected humans may shed a few
proglotids per day, a single carrier can be responsible for the
infection of multiple individuals and pigs in a community [1,2].
The manifestations of NCC are protean, but approximately
80% to 90% of persons with symptomatic NCC experience
seizures at some time in the course of their illness [3,4], making
this manifestation a reasonable starting point for identifying NCC
cases in populations at risk. Acute symptomatic seizures (seizures
occurring only in the presence of an acute central nervous system
(CNS) process) in NCC are thought to result from inflammatory
responses in the brain in response to a degenerating cyst [5].
Calcified intraparenchymal cysts may serve as a focus for remote
www.plosntds.org 1 December 2009 | Volume 3 | Issue 12 | e562symptomatic seizures as late sequelae of NCC [5], but there is not
always concordance between the location of calcified cysts and a
seizure focus identified by electroencephalogram [6].
The proportion of persons with acute symptomatic seizures
associated with NCC who go on to develop epilepsy (recurrent,
unprovoked seizures) is unknown, and determining the proportion
of seizures attributable to NCC is problematic in the absence of
repeated serological testing and concurrent diagnostic neuroim-
aging. In spite of these difficulties, NCC is considered to be the
leading preventable cause of epilepsy in developing counties [7–9].
Some of the studies used to support this contention have not
discriminated between acute symptomatic seizures and epilepsy or
have counted as NCC cases persons with seizures and positive
serology for T. solium (for example, Garcia et al., 1993 [10];
Nsengiyumva et al. 2003 [11]). In the absence of neuroimaging
evidence of brain lesions compatible with NCC, it is not possible to
determine whether infection with T. solium may be the cause of the
epilepsy. This is especially of concern in areas endemic for
cysticercosis where many people may be exposed to the eggs of the
parasite, including exposure after the onset of epilepsy. The
relation between number, location and stage of NCC lesions and
the presence and type of clinical manifestations further compli-
cates the discrimination between acute symptomatic seizures and
epilepsy in the field [10,12–15].
Alternatives to serology for identifying lesions of NCC in the
brain are computerized tomography (CT) or magnetic resonance
imaging (MRI) of the brain. The results of the imaging combined
with epidemiological and serological results have been suggested by
an international panel of experts for the diagnosis of NCC [16].
Reliance on neuroimaging studies for the diagnosis of NCC is not
generallyfeasible,however,especiallyindevelopingcountrieswhere
the disease is likely to be most prevalent and CT and MRI are often
not available. In addition, it is not a reasonable method for case
identification in community-based field studies of the epidemi-
ology of NCC. Development of alternative, valid strategies for
identifying persons with NCC would greatly facilitate such studies.
The first objective of this pilot study was to estimate the
proportion with NCC in persons attending an outpatient clinic for
epilepsy in an area of South Africa endemic for cysticercosis. A
second objective was to estimate the accuracy of antibody and
antigen serological testing in detecting cases of NCC in patients
with epilepsy.
Methods
The design of this study is cross-sectional.
Selection of Participants
Persons eligible for the pilot study were out-patients who were
attending the epilepsy clinic of St. Elizabeth’s Hospital in
Lusikisiki, Eastern Cape Province, South Africa. These patients
were either referred for seizures from a rural clinic or presented
themselves directly to the hospital for seizure diagnosis and care.
All individuals aged 5 years or older seen at St. Elizabeth’s
Hospital between July 2004 and April 2005 with possible new
onset epilepsy (incident cases) and those returning for continuing
care of epilepsy (prevalent cases) were invited to participate.
Clinical and epidemiological data were collected by local study
staff for all eligible consenting patients. Attempts were also made
to obtain blood samples from all participants in order to test for
the presence of antibody and antigen for T. solium.
Data Collection
A standardized questionnaire, adapted from Preux [9] and
developed by the Cysticercosis Working Group of Eastern and
Southern Africa (CWGESA), was administered in either English
or isi-Xhosa. Isi-Xhosa is spoken by the vast majority (95%) of the
black population in the Eastern Cape Province [17]. Translation
from English to isi-Xhosa and back translation to English was
done by two independent local residents who were fluent in both
languages. The interview included questions designed to screen for
epilepsy as well as information about potential risk factors for and
knowledge of cysticercosis and taeniasis, pig-keeping practices of
the household, and questions on their expenditures for medical
care for seizures. (Copies of the questionnaire are available on
request.) Mothers or primary care takers completed the interview
for children.
Clinical data for each participant, including the diagnosis of
epilepsy and the types of seizure manifestations, were provided by
the local co-investigator (G.S.-O.). The International League
Against Epilepsy (ILAE) classification of seizure types was used to
designate primary type of seizure based on descriptions of seizure
manifestations in the clinical data [18,19]. For these analyses,
epilepsy was defined as a clinical diagnosis of seizures in
combination with self-report from the questionnaire of ever
having had more than one seizure. At least two seizures separated
by at least 24 hours had to have occurred for a patient to be
diagnosed with epilepsy or recurrent unprovoked seizures. An
incident case of epilepsy was defined based on questionnaire
response as occurrence of first seizure within the past year.
Serological Testing
Serological testing for T. solium antibody and antigen was
offered to all participants. Serological testing for the presence of
antibody to T. solium was done using the ELISA method with
purified antigens (RIDASCREENH Taenia solium IgG commercial
diagnosis kit (R-Biopharm, Darmstadt, Germany)) [20]. Blood
serum samples were collected and transported from Lusikisiki to
Mthatha where serum was removed, aliquoted and frozen. One
frozen serum aliquot was transported to East London to detect the
presence of antibodies in the serum using an ELISA test. The
second serum aliquot was transported to the Medical Research
Council in Cape Town to detect the presence of antigens in the
serum using an ELISA.
The test used to detect antigens was the B158/B60 monoclonal
antibody-based ELISA developed by Dorny et al., 2000 [21]. For
this Ag-ELISA the calculation of the cut off is based on the results
Author Summary
Epilepsy is a significant contributor to morbidity world-
wide in persons of all ages. Little is known, however, about
its causes. In the developing world, parasitic infections of
the brain, in particular Taenia solium neurocysticercosis
(NCC) are thought to be important factors. Determining
whether or not there is infection in the brain is difficult
since to be certain, specialized imaging studies, such as CT
scans, are required. These are expensive and not widely
available. In addition, they are not appropriate for use in
large, population-based studies. Thus, blood tests for
evidence of infection with T. solium are often done instead
to estimate the presence of NCC. In this study’s population
of persons with epilepsy being seen at a hospital out-
patient clinic in South Africa, 37% had CT evidence of NCC,
a percentage similar to that reported in other developing
countries. The study also found that blood tests were not
generally useful compared to CT for correctly identifying
those persons who did or did not have NCC, and thus, they
cannot be relied upon for field studies of NCC.
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sample is compared with the mean OD of a series of eight samples
from non-infected individuals at a probability level of P,0.001 to
determine the result in the test [22]. The calculation is based on
Student’s t-test.
In some analyses, the results of the antigen-ELISA and
antibody-ELISA were considered together to define a positive or
negative result. If both measures were positive, the combined
measure was considered positive; if both were negative, the
combined measure was negative. A positive result to either test was
considered positive, even if the other result was missing. Similarly,
a negative result to either test was considered negative, even if the
other result was missing. These assumptions were considered
reasonable since among patients with both antigen and antibody
results available, 95% (38/40) of those with a negative antibody
result also had a negative antigen result. Only one person had data
missing for both antigen and antibodies.
Selection of Participants for the CT-Scan Examination
Each week, four randomly chosen patients with clinically
diagnosed seizure disorder and who gave written consent were
transported for CT scan of the brain (Toshiba Asteion TSX-021A)
to the Nelson Mandela Academic Hospital (NMAH), a teaching
hospital affiliated with the Walter Sisulu University for Technol-
ogy and Science in Mthatha. The transportation, per diem and
cost of the CT were covered by the research project and did not
incur any costs to the patients. When estimating the proportion of
cases associated with NCC, it is essential that seizure patients be
sampled randomly for CT in order to avoid persons suspected of
having NCC being preferentially referred. The random sampling
was done by first randomly selecting a day of the week (Monday
through Friday). The first four eligible patients at St. Elizabeth’s
seen on the randomly chosen day were referred to the NMAH. If
there were not four eligible patients on that day, the remaining
number required to reach a total of four were chosen from the first
eligible patients seen the following day. If the random day was
Friday and there were not four eligible patients on that day, then
the remainder were selected on the following Monday. CT scans
were done with and without radiographic contrast material for all
referred patients unless contrast was contraindicated (e.g., allergy
to contrast media, pregnancy). Scans were read by radiologists (IT,
MAA) at the NMAH as part of usual clinical care. Readings were
done without knowledge of serological results. For this pilot study,
results of the CT scans were used as the ‘‘gold standard’’ for
classification of NCC. We recognized that imaging is not a true
gold standard for the diagnosis of NCC but there were no other
imaging facility available to the patients in Mthatha. It is
reasonable, however, to assume that the CT-scan will be a much
better test for identifying lesions in the brain and a serological test.
Using the CT report results, cases were classified as ‘‘NCC’’ (either
evidence of visible cysticerci, colloidal cysts or presence of cerebral
calcifications with a specific CT diagnosis of NCC) or ‘‘not NCC’’
(no diagnosis of NCC and no evidence of cerebral calcifications of
any kind). Serology results were not used in making these
designations. Persons with CT scans interpreted as ‘‘cerebral
calcifications’’ but without mention of NCC and who had no
evidence of active cysticerci were included in one set of estimates
of the proportion of epilepsy associated with NCC but were
excluded from analyses of NCC in order to reduce the possibility
of misclassification.
Data Management and Analysis
All interview data were independently entered in an AccessH
database by two individuals. Questions for which there was a
disagreement of entries of more than 5% were reviewed and
corrected. Questions with disagreements of less than 5% were
consideredacceptable.Sixty percentofallentries had a mismatchof
2% or less. Prevalence proportion ratios, sensitivity, specificity and
predictive values were estimated. The 95 percent confidence
intervals (95%CI) of the field-based diagnosis of NCC were
calculated assuming a binomial distribution and using the exact
Clopper-Pearson method [23]. Data were examined for confound-
ing and interaction for all covariates, but since neither was present,
univariate results are reported. All analyses were conducted using
SAS version 9.1 (SAS Institute, Inc., Cary, North Carolina).
Consent Procedures
Two signed consent forms were used in this study. The first
consent form asked participants for their agreement to be
interviewed and have a blood sample drawn for the serological
analysis. A second consent was used for those patients selected at
random to have a CT-scan in Mthatha. This project was approved
by the Institutional Review Boards of the University of Oklahoma
Health Sciences Center, the Walter Sisulo University, and St.
Elizabeth Hospital.
Results
A total of 296 individuals with suspected epilepsy were seen at
the outpatient clinic in St. Elizabeth of whom 281 were diagnosed
with at least one seizure according to the clinical report. Socio-
demographic and clinical characteristics as well as serological
results from these patients are shown in Table 1. Ages ranged from
5 to 76 years with 31 (11.0%) cases being children (i.e., ,16 years
of age). The seroprevalence of antibodies and antigens to the larval
Table 1. Demographic, clinical, and serological characteristics
of 281 patients with seizures, St-Elizabeth Hospital Outpatient
Clinic, July 2004–April 2005.
Characteristic Category N % 95% CI
{
Number of participants 281
Age range 5–76 yrs.
Age group Children (,16 yrs) 31 11.0 7.6–15.3
Gender Female 163 58.0 52.0–63.8
Self-reported frequency
of seizures
Single seizure 17 6.1 3.6–9.5
More than one seizure 244 86.8 82.3–90.6
No answer 20 7.1 4.4–10.8
Primary seizure type Partial seizures 131 46.6 40.7–52.6
Generalized seizures 150 53.4 47.4–59.3
Reported duration of
seizures+
#1 year (incident) 63 28.9 23.0–35.4
2–4 years 50 22.9 17.5–29.1
5–9 years 37 17.0 12.2–22.6
$10 years 68 31.2 25.1–37.8
T. solium antibody* Positive 89 32.6 27.1–38.5
T. solium antigen* Positive 15 7.9 4.5–12.8
Brain CT Yes 111 39.5
{95% confidence interval.
*of those tested (antibody testing, n=273; antigen testing, n=188).
+of those who answered duration question and had available seizure frequency
data (n=218 of 281).
doi:10.1371/journal.pntd.0000562.t001
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(95%CI: 4.5%–12.8%), respectively. Generalized seizures were
reported slightly more often than partial seizures. Of the
generalized seizures, tonic-clonic were most often reported, and
the most commonly observed partial seizures were either complex
partial seizures with motor manifestations (n=79, 28.1%) or
partial seizures secondarily generalized (n=40, 14.3%). A total of
244 patients (86.8%, 95%CI: 82.3%–90.6%) met our definition of
epilepsy. Among those with epilepsy, the onset of seizures was
within the past year in 28.9% (95%CI: 23.0%–35.4%) of cases,
while another 31.2% (95%CI: 25.1%–37.8%) had been having
seizures for 10 years or longer at the time of this study.
Since the referral of patients for CT was done randomly, the
characteristics of those with and without CT are expected to be
similar. There were more patients sent for CT for whom seizure
frequency was unknown (13.5% vs. 2.9%) and more children aged
less than 16 (16.3% vs 7.2%), but no other statistically significant
differences were observed in demographic, seizure type or
duration, or serological results between those who were or were
not referred for CT. The distributions of demographic and clinical
characteristics of those referred as compared to those not referred
for a CT scan are given in Table S1.
A total of 92 patients who met the study’s definition of epilepsy
received a CT scan. Of those, 34 (37.0%, 95%CI: 27.1%–47.7%)
had a CT diagnosis of NCC; 20 (21.7%; 95%CI: 13.8%–31.6%)
of these showed calcification with a diagnosis of NCC and 14
(15.2%; 95%CI: 8.6%–24.2%) had either visible cysticerci or
colloidal lesions (subsequently referred to as ‘‘active’’ NCC). In
these two groups, the proportions with new-onset seizures were
31.6% (95%CI: 12.6%–56.6%) and 46.2% (95%CI: 19.2%–
74.9%), respectively. If persons with epilepsy who had CT
evidence of cerebral calcifications not diagnosed as NCC
(n=19) were included as possible cases of NCC, the proportion
of epilepsy associated with NCC would be 43/92 or nearly 47%.
These 19 uncertain cases were excluded from further analysis of
NCC as these lesions may be due to other cerebral infections such
as tuberculosis. Some cases of NCC may have been missed by this
approach, which would under-estimate the proportion of seizure
cases associated with NCC. Excluding them has the benefit,
however, of reducing the chances of misclassification within the
NCC group, which increases the validity of the comparisons
between NCC and non-NCC epilepsy cases.
Characteristics of those with calcified NCC lesions, ‘active’
NCC, and those with no CT abnormalities are summarized in
Table 2. Those with ‘active’ lesions were less often female and
more often seropositive than those with calcified lesions or those
with no CT abnormalities.
Prevalence proportion ratios for selected characteristics were
calculated comparing those with: 1) any definite NCC diagnosis to
those with no CT abnormality, and 2) those with ‘active’ NCC to
those with no abnormality (Table 3). The small number of cases in
each group is reflected in the wide 95% CI. When compared to
those with epilepsy who had no CT abnormalities, the proportion
of incident cases of epilepsy tended to be higher in those with NCC
(PPR=1.97, 95%CI: 0.87–4.42) and even higher in those with
‘active’ NCC (PPR=2.39, 95%CI: 0.97–5.89). The prevalence of
a positive antibody test was higher in those with NCC
(PPR=1.77, 95%CI: 1.01–3.12), especially in those with ‘active’
NCC (PPR=2.55, 95%CI: 1.48–4.40) as compared to those
without NCC. Compared to those with calcified NCC lesions, the
prevalence of seropositivity for antibody to T. solium was 2.55 times
higher (95%CI: 1.48–4.40) in those with ‘active’ NCC.
The validity of serological testing for antibodies or antigens as
diagnostic tools for NCC in persons with epilepsy was estimated
separately (Table 4). The predictive value for NCC of a positive
antibody test was 60.0% (95%CI: 40.6%–77.3%). Hence, 40%
(95%CI: 22.7%–59.4%) of those testing positive to the antibody
ELISA but without NCC would be falsely attributed to NCC (false
positives) based on serology alone. When this analysis was confined
to those who had ‘active’ NCC, the sensitivity of serology in
epilepsy patients was higher (78.6%, 95%CI: 49.2%–95.3%).
However, since the prevalence of ‘active’ NCC is lower than that
of all NCC, the predictive value of a positive antibody test in these
patients was reduced to only 47.8% (95%CI: 26.8%–69.4%),
therefore leading to 52.2% false positives.
The predictive value of a positive antigen test was similar to that
for antibody at 66.7% (95%CI: 22.2%–95.7%) but the sensitivity
was very poor at 17.4% (95%CI: 5.0%–38.8%). When the validity
of antigen testing was examined only among those with ‘active’
NCC lesions, the predictive value for a positive antigen test was
50.0% (95%CI: 6.8%–93.2%).
Table 2. Comparison of characteristics in epilepsy patients in
those with a CT diagnosis of NCC calcifications, those with
‘‘active’’ NCC and those with no CT abnormalities.
Characteristics Category
NCC Dx**
(n=20)
‘‘Active’’
NCC (n=14)
No
abnormality
(n=39)
Age group $16 years 15 (75%) 11 (78.6%) 32 (82.1%)
Gender Female 12 (60%) 6 (42.9%) 24 (61.5%)
Seizure type Partial 6 (30%) 7 (50%) 18 (46.2%)
Generalized 14 (70%) 7 (50%) 21 (53.8%)
Reported duration
of seizures
#1 year
(incident)
6 (31.6%) 6 (46.2%) 7 (19.4%)
2–4 years 3 (15.8%) 2 (15.4%) 10 (27.8%)
5–9 years 5 (26.3%) 2 (15.4%) 6 (16.7%)
$10 years 5 (26.3%) 3 (23.1%) 13 (36.1%)
T. solium antibody Positive 7/19 (36.8%) 11/14 (78.6%) 12/39 (30.8%)
T. solium antigen Positive 2/13 (15.4%) 2/10 (20%) 2/22 (9.1%)
See text for complete definition of the result groupings.
**Dx=diagnosis.
doi:10.1371/journal.pntd.0000562.t002
Table 3. Prevalence proportion ratios (and 95% confidence
intervals) comparing characteristics of those with any NCC
(n=34) to those with no CT abnormality (n=39) and of those
with ‘‘active’’ NCC (n=14) to those with no CT abnormality.
Characteristic
All NCC vs no
CT abnormality
‘‘Active’’ NCC vs
no CT abnormality
Age,16 yrs 1.31 (0.74–1.18) 1.19 (0.36–3.99)
Male Gender 1.22 (0.72–2.09) 1.49 (0.81–2.71)
Partial Seizures 0.83 (0.48–1.43) 1.08 (0.58–2.02)
Incident epilepsy* 1.97 (0.87–4.42) 2.39 (0.97–5.89)
Ab positive 1.77 (1.01–3.12)** 2.55 (1.48–4.40)
"
Ag positive 1.91 (0.39–9.41)
1 2.20 (0.36–13.47)
6
*Seizure onset within past year (n=68).
**Based on 72 observations.
"Based on 53 observations.
1Based on 39 observations.
6Based on 32 observations.
doi:10.1371/journal.pntd.0000562.t003
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NCC if only those with new onset (incident) seizures were assessed.
Unfortunately, there were only 14 patients with new onset seizures
who had a CT-scan and either antigen or antibody serology
performed. Nonetheless, analysis in this small group suggested that
being seropositive for T. solium may be a good field diagnostic tool
for NCC among incident seizure cases (predictive value of positive
serology=80%, 95%CI: 44%–98%), although 40% (95%CI: 5%–
85%) of those whose seizures are not related to NCC will be falsely
categorized by serology as NCC.
A series of comparisons was made between those who were
correctly and incorrectly classified as NCC by serology (antibody
ELISA or antigen ELISA) in order to see whether there were
characteristics that distinguished them. Serological true positives
(CT positive for NCC and seropositive) and false negatives (CT
positive for NCC but seronegative) as well as serologically true
negatives (CT negative for NCC and seronegative) and false
positive (CT negative for NCC and seropositive) are compared in
Table 5. The small numbers in each group are reflected in the
wide 95% CI. More true positives had ‘active’ lesions (PPR=3.06,
95%CI: 1.04–8.97) than false negatives. Persons with epilepsy who
are falsely identified as cases of NCC based on serology were more
often present or past owners of pigs (PPR=1.35, 95%CI: 1.08–
1.69) and had a higher prevalence of incident seizures
(PPR=1.23, 95%CI: 1.02–1.47) compared to those correctly
identified by serology as epilepsy not due to NCC.
Discussion
The source population for this study included persons seeking
medical care for symptomatic seizures (acute seizures) or recurrent
asymptomatic seizures (epilepsy) at an outpatient clinic of St.
Elizabeth Hospital, a rural hospital in Lusikisiki, Eastern Cape
Province, South Africa. While the study includes consecutive,
unselected epilepsy patients, this group does not represent a
community-based sample of persons with epilepsy since only those
seeking care are represented. The characteristics of these patients
with respect to age distribution and seizure types were similar,
however, to those observed in community-based studies of epilepsy
conducted in sub-Saharan Africa [9,11,24].
Nearly one-third of epilepsy patients were seropositive to T.
solium antibodies. This proportion is within the range of that
reported from endemic countries of Sub-Saharan Africa using the
antibody-ELISA test [25,26].
When CT results are used to identify NCC, the proportion of
epilepsy patients with evidence of NCC was 37%, which is higher
than what would have been identified based on either ELISA test.
This proportion is also comparable to many reports based on
neuroimaging findings from other endemic regions [25,27]. Only
15% of those with seizures had lesions with either a demonstrated
scolex or that were described as colloidal or cystic; seizures in these
patients may be more correctly classified as acute symptomatic
seizures.
One of the aims of this pilot study was to estimate the validity of
serological testing for T. solium, as a readily available classification
tool in the field, in identifying persons with NCC among those
with epilepsy or recurrent seizures. When using CT-scan results as
the ‘‘gold standard’’, only 60% of those seropositive to the
antibody to T. solium truly had NCC and nearly one-third of those
truly without NCC would be wrongly identified as NCC based on
serology alone. Also, more than one-third of those seronegative to
the antibodies of T. solium had NCC, and would thus not have
been diagnosed using this field-based criterion. Some of the
relatively poor sensitivity and specificity of serology in correctly
identifying persons with NCC may be a result of the antibody
ELISA test used in this study, which is based on purified antigens.
However, in a study conducted using 67 sera and 53 CSF samples
from confirmed cases of NCC in Chile, the sensitivity and
specificity of the ELISA using a purified antigen was 97% and
98.3% for the serum samples, respectively [28]. We have used a
commercially available kit which may have slightly different
accuracy values. Other antibody ELISA tests using crude extract
of the metacestodes have shown some limitations. In a double
blind, head-to-head comparison in the same population in which
only 6% of NCC cases had calcified lesions, EITB was more
sensitive than antibody-ELISA based on crude extract of the
metacestode in detecting antibody to T. solium (86% vs. 41%
respectively) but approximately equal in specificity (93% v. 96%,
respectively) [13]. In populations in which the proportion of NCC
with calcified or single lesions is high, both the ELISA test using
crude extract of the metacestode [13] or the EITB [29,30] have
significantly reduced sensitivity.
We found that antigen testing was very poor for identifying
persons with NCC, even among those with active disease. This is
likely due to the natural history of NCC in which the incubation
period for CNS manifestations is not clearly understood but
appears to be extremely variable; symptoms can occur many
years after the primary infection [31]. While the breakdown of
cysts in the brain and subsequent release of parasite antigen is
thought to trigger an inflammatory response which results in
acute CNS manifestations in NCC [5], antigens in the CNS may
not be present at detectable levels in the serum. This would be
contrary, however, to what has been demonstrated for
antibodies detectable by EITB, in which samples from sera
were more often positive than samples from cerebral spinal fluid
[13]. Unfortunately, this pilot study was too small to examine the
Table 4. Estimated validity of field-based criteria
(seropositive to antibodies and antigens of cysticercosis
separately) for the diagnosis of all NCC and ‘‘active’’ NCC in
persons with epilepsy.
FIELD-BASED
RESULT CT SCAN RESULT
All NCC ‘‘Active’’ NCC
NO CT
Abnormality
Antibody
Antibody positive 18 11 12
Antibody negative 15 3 27
Field diagnosis
validity (%)
Sensitivity: 54.5
(36.4–71.9)
Sensitivity: 78.6
(49.2–95.3)
Specificity: 69.2
(52.4–83.0)
Positive predictive
value (%)
60.0 (40.6–77.3) 47.8 (26.8–69.4)
Negative predictive
value (%)
64.3 (48.0–78.4) 90.0 (73.5–97.9)
Antigen
Antigen positive 4 2 2
Antigen negative 19 8 20
Field diagnosis
validity (%)
Sensitivity: 17.4
(5.0–38.8)
Sensitivity: 20.0
(2.5–55.6)
Specificity: 90.9
(70.8–98.9)
Positive predictive
value (%)
66.7 (22.2–95.7) 50.0 (6.8–93.2)
Negative predictive
value (%)
51.2 (34.8–67.6) 71.4 (51.3–86.8)
doi:10.1371/journal.pntd.0000562.t004
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seizures.
False negatives, i.e., those with NCC by CT but with negative
serology, were less likely than true positives to have new onset
seizures. Failure to identify these cases by antibody or antigen
serology as possible NCC is compatible with the reported decline
in detectable levels of antibody to T. solium over time [10,32] and
is a potential source of significant misclassification of NCC in all
prevalence studies that use serology to detect antibodies, either
with ELISA or EITB, to identify NCC in persons with epilepsy
[33]. In addition, the performance of antibody-detection test
(EITB) has been shown to be reduced among NCC cases
showing single, small enhancing lesions [30]. False positives (no
NCC by CT but seropositive) likely include persons whose
epilepsy is from other causes who are seropositive for T. solium
b e c a u s et h e yl i v ei na ne n d e m i ca r e a .P e o p l ew h oa r ep o s i t i v et o
the presence of antibodies may have been infected in the past or
may have been exposed to the cysts and developed sufficient
antibodies to prevent the cysts from establishing in the body.
People who are positive to the presence of antibodies or antigens
may be infected with the cyst elsewhere in their body. These
groups contribute to the over-estimation of the proportion of
epilepsy due to NCC when only serological testing is used to
identify cases.
In this study, neuroimaging by computerized tomography
was used as the ‘‘gold standard’’ against which serology was
compared; no MRI facilities were available in the study area.
Misclassification of NCC based on CT would occur if the scan
missed existing lesions (false negatives) or if lesions were
misidentified as NCC (false positives). If present, such misclassi-
fication in the ‘‘gold standard’’ would impact the apparent
performance of serology. The potential for false positives was
reduced by excluding those with calcifications of uncertain nature
and also by assessment of the validity of serology to the subset of
cases with CT evidence of cysterci. This latter group is unlikely to
be misclassified. CT and MRI are equally valid for parenchymal
lesions, such as those in the present study [34,35], while CT is
considered superior to MRI for identifying calcified lesions, which
represented 59% of NCC cases in the present study [15,34].
Misclassification of serological results was reduced by requiring
that results be definitely positive; those with intermediate results
were not counted as seropositive.
The data available for the present study made it difficult to
separate symptomatic seizures from epilepsy. We did include as
epilepsy only those who self-reported having had more than one
seizure episode and clearly, the duration of seizures was very
l o n gf o rm a n yi n d i v i d u a l s ,b u tt h ep r e s e n c eo fs o m ea c u t e
symptomatic seizures cannot be ruled out. It is interesting to
note that the predictive value of positive serology for antibody to
T. solium was highest in those with either visible cysteci or
colloidal lesions on CT, suggesting that antibody testing might
be useful for identifying acute symptomatic seizures, but not
epilepsy.
The use of serological testing as a method for identifying cases of
NCC in the field will continue to be inadequate because of the
natural history of NCC. Although not fully understood because of
the absence of cohort data, available cross-sectional and case-
control information has helped to define some aspects of the
disease which impact on the validity of any attempt to measure it
in population settings. These characteristics include the evolving
nature of the CNS lesions and how the location, stage and number
of lesions may affect the clinical manifestations of NCC
[5,10,12,14,15]; the unknown nature of the balance between
intensity of infection and measurable antibody levels vs. CNS
invasion; the duration of measurable antibody and antigen levels
in relation to the presence of observable CNS involvement
[10,32]. Given these limitations, it is unlikely that even improved
serology will alone be sufficient for the valid identification of
persons with NCC.
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Table 5. Distribution and associated prevalence proportion ratios (PPR) of demographic and clinical characteristics of 33 epilepsy
patients with CT-diagnosed NCC lesions and 39 patients without CT-scan lesions of NCC according to serological field-based
diagnosis (antigen or antibody ELISA positive).
Characteristic Field-based classification
True positive
(n=18)
False negative
(n=15) PPR* (95% CI)
True negative
(n=27)
False positive
(n=12) PPR** (95% CI)
Age,16 yrs 5 (27.8%) 2 (13.3%) 2.08 (0.47–9.24) 4 (14.8%) 3 (25.0%) 1.69 (0.44–6.40)
Male gender 9 (50.0%) 6 (40.0%) 1.25 (0.58–2.71) 7 (25.9%) 5 (41.7%) 1.61 (0.67–4.26)
Generalized Seizure 11 (61.1%) 10 (66.7%) 0.92 (0.55–1.53) 11 (40.7%) 7 (58.3%) 1.43 (0.74–2.77)
Active NCC by CT 11 (61.1%) 3 (20.0%) 3.06 (1.04–8.97) NA NA NA
Ever kept pigs 14 (82.4%) 11 (78.6%) 1.05 (0.74–1.49) 20 (74.1%) 12 (100%) 1.35 (1.08–1.69)
Reported duration of
seizures#1 year
+
8 (47.1%) 4 (28.6%) 1.65 (0.62–4.34 22 (81.5%) 12 (100%) 1.23 (1.02–1.47)
*PPR: prevalence proportion ratio calculated as % true positive with factor 4 % false negative with factor).
**PPR: prevalence proportion ratio calculated as % false positive with factor 4 % true negative with factor).
+Reported duration of seizures based on 31 observations for the true positive, false negative comparison.
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